Junior Division

Challenge 1
Nanofirst hopes one day to be able to deploy primary response nanotechnology by drone to patients. This could be a challenge because if the primary response is drones, then those with jobs like paramedics or emergency response jobs will be negatively affected and may lose their jobs. This might lead to the basic needs of those being jeopardized.

Challenge 2
Europe and Asia have been using nanotech for years, and it's time Australia caught up. This could be a challenge because Europe and Asia may have unfair advantages in their development, while others in Australia may have worse healthcare. This may lead to the physical health of the citizens in Australia being negatively affected.

Challenge 3
The social feeds always love to focus on a worst case scenario on Nanofirst as they give it much more problems. This may be a challenge because the social feeds may mislead others who are unsure about Nanofirst. This may lead to the public image of Nanofirst being displayed wrongly.

Challenge 4
Dr Robbin’s doesn’t care what the Nanofirst diagnostic advice is, and doesn’t listen to it. This could be a challenge because the doctors are then not trusting of the AI and might make wrong choices about people when AI is correct. This might lead to doctors not working well with AI putting the citizens of Australia at risk of other diseases.

Challenge 5
Nanotech offers the capability of administering oxygen directly to brain and heart tissue, but when two nanotechnology companies’ technology are incompatible, the nanotech can’t get into the tissues. This could be a problem because medical patients with illnesses may not be able to receive the nanomedicine they need due to a previous nanotech treatment with a separate company. This could lead to the physical health of medical patients using nanotechnology being negatively impacted.

Challenge 6
There has been evidence that exposure to ClotBots in utero can increase the risk of blood-clotting disorder later in life. This could be a problem because pregnant individuals may endanger their fetus while receiving ClotBots with nanomedicine for a different medical issue. This could lead to the physical health needs of a pregnant women and their fetus being affected, causing ethical questioning of the nanotech from the public.

Challenge 7
The unions are concerned about whether some jobs will be lost, especially when nanotech is combined with drones and co-bots. Nobody knows yet how many jobs will be affected. This could be a problem because individuals that have jobs in the medical industry might lose their source of income. This could lead to the basic needs of individuals in the industry being affected because they might be unable to receive necessary resources without a stable job.

Challenge 8
The future scene states “Dr Robbins wonders if it is true incompatibility or just corporations protecting their intellectual property and market share.” This may be a challenge because some people may have gotten sicker due to the “incompability” of the two nanotechnologies. Hence, the corporations could be seen as dishonest, disrupting their business and people’s physical health.

Challenge 9
A skier from Germany lost her tattoos to another company’s emergency nanotech after an accident in the mountains. This may be a challenge because if this nanotechnology is changing physical appearances, the business could be corrupted due to complaints. Hence, the aesthetics of people using nanotech and the business of nanotechnology may be negatively affected.

Challenge 10
The future scene states “he makes a blink-swipe gesture to begin”, and a “clenched fist to close display”. This may be a challenge because the display could be accidently opened as people blink naturally, and they might unintentionally swipe their hand. Furthermore, if someone were to have a hand injury or something that prevented them from clenching their fist, it would be very inconvenient. Hence, the technology of the Australian nanotech business does not cater to all needs, and could be seen as ableist.

Challenge 11
Xander, an “excellent paramedic”, is known to be-overly careful, so is less likely than others to implement Nanofirst in treatment. This may be a challenge because if someone needs Nanofirst urgently to maintain adequate health, Xander’s paranoia can deprive people from the Nanotech they need. Hence, the physical health of citizens may be negatively affected.

Challenge 12
Ella says "First they say I have to babysit this bot. Now the bot is telling me what to do.” This may be a challenge because if the bot requires supervision while also being in charge, this on and off working technique can irritate employees, hindering them from reaching their full potential. Hence, the business of Australian nanotech could be disrupted.

Challenge 13
Dr Robbins wishes he could outsource the media work to an AI avatar, but human connection was needed for people to start to trust nanotechnology. This may be a challenge because the media and people are focusing on the wrong issue, they are focusing on having a human instead of AI when they should be worried about whether or not they need nanotechnology. This may lead to educational errors.

Challenge 14
Because there have been claims that patients in critical condition cannot give informed consent for EMS nanotech, several complaints about adverse events have been lodged with the TGA. This may be a challenge because the company could face issues related to defence. This may lead to the business declining, and the physical health of the patients being jeopardized.

Challenge 15
Because Nanofirst is not designed for long term function, it could lead to issues in the future. This may be a challenge because it could risk someone's life and the company could be viewed as untrustworthy. This could lead to physical health damage and the economy of Nanofirst declining.

Challenge 16
The future scene states “but as usual his virtual assistant has misunderstood which issues are most important for human health wellbeing, it’s not the order he would choose.” This may be a challenge because it shows that the AI virtual assistant isn’t very advanced, inferring that it could make other mistakes. This could lead to issues in the system.

Underlying Problem
Because Nanofirst cannot safely administer treatment to individuals who have nanotechnology treatments with other incompatible companies, how might we bolster Nanofirst’s treatment processes on all medical patients so that all citizens with medical issues can effectively utilise nanotechnology in Medicine in Queensland, Australia, in 2042 and beyond?

Solution 1
The Nanorobotics Cell Delivery Company (NCDC) will create nanorobots that will deliver straight to cells. This makes sure that there is no chance for incompatible nanoparticles to react with each other. After that, the cells will be marked and then other treatments will be injected into the other cells. This will solve our UP because then the nanotechnology will not be able to mix and become incompatible.

Solution 2
The Nanogold Drug Corporation (NDC) will make nanogold nanoparticles that are used to transport drugs to the body. The nanogold will have antibacterial properties, and will be injected into the body like vaccinations. The nanogold will have drugs contained that will have nanotechnology treatments, and will release them after the outer layer is broken. This will solve our UP because it will bolster the Nanofirst treatment processes.

Solution 3
Nanoscientists will work with genetic scientists to create “genanotechnology”. This genatech will be administered into the body at the early stages of the growth, it will then grow within the body, growing personalized to the body it is in by collecting data from the genetics and DNA of the patient. This solution solves the Underlying Problem by bolstering the treatment by making it personalised for the citizen.

Solution 4
The Digital Twiners (DT) will create a specialised digital twin variant for this issue. The DT will be able to test the nanoparticles in different medical emergency scenarios, seeing where it needs improvement. The Nanofirst company can then take this data, research it and try and bolster the treatment processes on citizens, solving our Underlying Problem.

Solution 5
The Reaction Medicine Group (RMG) will react the two medicines together and check if they still have their medicinal properties. Then they will inject the medicine into the person’s body so the compatibility of the medicine will not affect them. This will solve our UP because the safety of the people with the medicine will be bolstered.

Solution 6
The Tube Treatment Team(TTTT) will create a treatment process by inserting the human body(about to receive the treatment) through a tube made of soft synthetic material, and allowing the nanotechnology to soak into the body in a safe manner as it reaches the heart tissue immediately. This solution solves our Underlying Problem as the nanotechnologies can now securely enter the human body.

Solution 7
The Nanoparticle Creators Club (NCC) will create nanoparticles that have antibacterial properties to transport medicine into the body. The antibacterial nanoparticles will then be used so that bacteria will not be able to infect it. This will solve our UP because this solution will bolster the medical processors of Nanofirst.

Solution 8
The Liquid Glass Group (LGG) will create a liquid glass that is
edible, which will be taken by the patient. It will stay in the body until it detects nanotechnology. It will then go towards the nanotech particles and wrap itself around it, making a coating. It will be flexible and breathable, as well as being transparent and nontoxic. This will solve the Underlying Problem by protecting the body and other nanotechnology particles from being incompatible to each other.

Solution 9
The Human Robot Engineers (HRE) will create a robot with sensors which are similar to human traits in the skin. The robots will then be put into scenarios where they are in need of medical assistance to see if they experience any nanoparticles malfunctioning, which could hurt the humans health. The information will then be used to track down the source of error and the nanoscientists will then fix it. This will solve our UP because then the treatment processes on patients will be bolsters, effectively utilising nanotechnology for citizens with medical issues.

Solution 10
The Holographic Display Scientists (HDS) will create a hologram that detects potential issues with the nanotechnology getting into the tissue. The hologram will scan the construction site and identify potential dangers to humans. They will then suggest solutions or ways to stop the toxicity by using an AI as well as human brainstorming. This will bolster Nanofirst’s treatment processes on patients.

Solution 11
Nanoscientists and chemists will create a nanoantibiotic. The antibiotic nanoparticles will destroy bacteria resistant to normal drugs. They attach to bacterial membranes and release chemicals or heat that kill bacteria instantly. This will help solve the Underlying Problem by efficiently utilise nanotechnology to bolster the treatment process of Nanofirst.

Solution 12
Nano scientists will create a layer of black phosphorus nanoparticles that will take in the nanoparticles and cover them. After, it will decompose with the nanoparticle and turn into an enzyme that the body can use. This will solve our UP because the medical processes of Nanofirst will be bolstered.

Solution 13
Scientists and chemists will work with the two corporations to create a combination of Nanofirst and SANOSURGE, making them mix safely before inserting it into the body. After the concoction is thoroughly mixed, it is injected into the bloodstream, allowing both companies to work together. This is potentially also better business for them as more people will be able to use both of these nanotechnologies.

Solution 14
The Nanochip Set Up (NSU) will create a nanochip. This nanochip will be inserted into the body via injection that will make the two types of nanotechnology compatible. This will solve our Underlying Problem by making the incompatible companies compatible.

Solution 15
Technologists will work with The Magnet Company(TMC) to create autonomous magnets that will guide metal nano drug carriers throughout the body. The drugs in these carriers allows Nanofirst and SANOSURGE’s nanotechnologies to safely mix. This solves our Underlying Problem because the two nanotechnologies are now compatible and able to be entered into the human body safely.

Solution 16
The government of Australia will pass a law that all companies or corporations will prioritise health and safety of its customers and clients over protecting their own intellectual property and market share. If this law is broken, the companies will face various levels of prosecution depending on how severe the violation is. This solves our Underlying Problem because it protects the patients by defending their health and safety.

Criterion 1
Which solution will best bolster Nanofirst’s treatment processes on patients who may not be able to adequately receive nanomedicine in Queensland?

Criterion 2
Which solution will most allow citizens with medical issues to effectively utilise nanotechnology in Medicine in Queensland?

Criterion 3
Because Nanofirst cannot safely administer treatment to individuals who have nanotechnology treatments with other incompatible companies, which solution will best allow the safest reaction to Nanofirst’s treatment administration for medical patients?

Criterion 4
Because there has been evidence that exposure to ClotBots in certain organs can increase the risk of blood-clotting disorder later in life, which solution will most minimize the potential of blood-related diseases on patients using Nanofirst’s medical treatment?

Criterion 5
Because Nanofirst’s treatment with nanotechnology is a new development using non-traditional methods, causing a potential for questioning from the public, which solution will be the most accepted by the citizens of Australia using Nanofirst’s nanomedicine?

ALoU 1

Solution #:
1

Summary:
The Nanorobotics Cell Delivery Company (NCDC) will create nanorobots that will deliver straight to cells. This makes sure that there is no chance for incompatible nanoparticles to react with each other.

Advantages:
The advantages of this solution are that:
- bolster the treatment processes on patients
- effectively allows citizens with medical issues to utilise nanotechnology
- no side effects
- no chance for incompatible nanoparticles to react with each other
- antibacterial

Limitations:
The limitations of this solution are that:
- large production mass
- costly
- Nanorobots could accumulate in the body

Unique Possibilities:
The unique possibilities of this solution are that:

- drug cells will be distributed evenly
- no replacing of the companies (no economic and basic needs problems)

Action Plan
The Nanorobotics Cell Delivery Company (NCDC) will create nanorobots that will deliver nanomedicine to the cells. This makes sure that there is no chance for incompatible nanoparticles to react with each other. After that, the cells will be marked and then other treatments will be injected into the other cells.


The nanorobots will be made up of synthetic metals that will be created by material scientists that will be coated with antibacterial nanoparticles. The nanorobots will then be programmed by coders and tested by them. They will be injected into the skin, where they will travel through the person's bloodstream to the affected point that needs medicine. The nanorobots will then deliver the nanomedicine to every second cell and mark it slightly to show that it has been delivered there. Then the nanorobots will deliver another drug to the other cells that haven’t had any drugs delivered there yet. This makes sure that the medicine does not react together, even if they are incompatible. After the nanorobots have finished delivering drugs, they will decompose into vitamins, healthy chemicals and enzymes that are good for the body and used for consumption. The body will be able to naturally dispose of any residue from the nanorobots, reducing the risk of nanorobot accumulation.


This solution received an 8 for bolstering Nanofirst’s treatment processes on patients who may not be able to adequately receive nanomedicine in Queensland (criteria#1). This is because the solution will allow the nanotechnology to remain isolated, stopping mixture and incompatibility between different technology treatments. The solution received an 8 for allowing citizens with medical issues to effectively utilise nanotechnology in Medicine in Queensland (criteria#2). This is because the solution will allow citizens with medical issues to safely use nanotechnology to its full benefits, by reducing the risk of contamination between treatments. The solution received a 6 for allowing the safest reaction to Nanofirst’s treatment administration for medical patients because Nanofirst cannot safely administer treatment to individuals who have nanotechnology treatments with other incompatible companies (criteria#3). The reason for this scoring is because the solution can increase the chance of safer administration and lessen the chance of negative reaction, but the solution cannot guarantee safe reaction for patients. The solution received a 5 for minimizing the potential of blood-related diseases on patients using Nanofirst’s medical treatment because there has been evidence that exposure to ClotBots in certain organs can increase the risk of blood-clotting disorder later in life (criteria#4). This is because the solution can decrease the risk of unsafe distribution of the treatment in the bloodstream and reduce the risk of blood diseases, but isn’t specifically focussed on blood-related aspects, thus it is not the best solution for minimizing potential blood-related diseases on patients. This solution received a 6 for being the most accepted by the citizens of Australia using Nanofirst’s nanomedicine because Nanofirst’s treatment with nanotechnology is a new development using non-traditional methods which could cause questioning from the public (criteria#5). This is because although the solution is the safest option, it still uses new nanotechnology methods that may not be accepted by the general public.


The advantages of the solution are that it bolsters the treatment processes on patients, it effectively allows citizens with medical issues to utilise nanotechnology, thus solving the Underlying Problem, it provides no side effects for patients using the Nanofirst treatment, and there is no chance for incompatible nanoparticles to react with each other. The limitations are that it has a large production mass, the solution is very costly, and that Nanorobots could accumulate in the body. To solve the limitations, Nanofirst will use sustainable materials and use stable funding processes to manufacture the nanorobots. Nanofirst will also add a synthetic liquid to allow the robots to decompose into useful enzymes that the body can use, to solve the limitation of nanorobot accumulation. The unique possibilities of the solution is that the drug cells will be distributed evenly in the body and feed of illness, and will not acquire economic or basic needs problems as it will not replace jobs or companies.


On November the 1st, 2042, the Nanorobotics Cell Delivery Company (NCDC) will ask artists from the Nano-Artists Guild (NAG) to design layouts for the nanorobots. They will have one month to perfect and refine their design, ending on December 1st. After that, they will ask nanoparticle specialists to find decomposable and antibacterial metals that will be used to coat the nanorobots, finishing on January the 30th. Then coding experts will be bought in to help code the nanorobot. The code will be due on February the 30th. They will test the code in a digital twin and solve any of the problems with it, ensuring it is efficient and effective, finishing on the 1st of April. They will test each metal in digital twins of a human’s body to see if they pose any dangers to them, finishing on 20th of April. The Nanorobots will then be used to supply common medicinal drugs to people in the digital twin, and data analysts as well as scientists will try to find problems that they solve, solving them around the 25th of May. Afterwards, they will make sure the robots are decomposable in the human body by replicating the environment in a digital twin. They will make sure that the robots decompose within a day or 24 hours. This will finish on the 1st of JuneThen they will supply the nanorobots to patients who volunteer and see if they act the same around human bodies. They will then be released to the public for commercial and medical use on the 30th of June. They will also have feedback systems to improve the design or the coding of it, which will go on forever.


A potential problem of this solution is that the nanorobots may accumulate in the body. This limitation can be solved by slightly bolstering the medical chemical processes. Nanoscientists will work with specialised and professional chemists to allow the nanorobots to decompose after being in the body for a week. It will decompose into vitamins and nutrients, in the bloodstream. Not only does this solution solve the problem, it also becomes a unique possibility.


This solution will solve our Underlying Problem because the nanomedicine from different companies will not be able to mix together if they are incompatible towards each other. People will be able to receive both medicines without any unwanted chemical reaction. The nanorobots are also decomposable, meaning they will not accumulate inside the body. This solution impacts the future scene, as one of the large problems was the incompatibility of the medicines with the Nanofirst nanomedicines.